Cystic fibrosis (CF) is a monogenic genetic disorder caused by mutations in CFTR, and respiratory disease is the major cause of morbidity and mortality. The median age of survival in CF is only 37 years, but there is a broad range of disease severity in the lung, even among patients with identical CFTR genotypes, including ?F508 homozygotes. Robust twin/sib studies conclude that genetic factors must play a critical role in disease severity. Two transformational studies of twins and sibs assessed environmental versus genetic influences, and both concluded that genetic factors play a major, or even majority, role in lung disease severity, and heritability estimates ranged from 0.54 to 0.89. Early candidate gene studies to identify CF modifiers were limited by small sample size and poorly defined phenotypes. These limitations have been addressed by a North American CF Genetic Consortium, which includes study groups at UNC/CWRU, Johns Hopkins, and Toronto. Genetic Modifier Consortium patients are now being tested in a whole-genome scan (Illumina 610K Quad). This RFA now provides the opportunity to study the role of gene expression variation in CF lung disease, and the integrated analysis of SNPs/CNVs and expression data. This project holds great promise for defining a robust molecular phenotype for CF lung disease, and we will be uniquely positioned to develop an integrated view of molecular mechanisms underlying CF lung disease severity. Since most CF patients are now diagnosed by neonatal screening, each CF patient could have a molecular signature, and associated risk, established early in life. Taken together, expression data and whole genome SNP data in the same CF patients are likely to spawn a variety of biological and clinical research activity in CF (and other) lung diseases, and provide unprecedented opportunities for novel prognostic and therapeutic interventions in CF. The identification of molecular mechanisms relevant to lung disease severity in CF is also likely to be relevant to more common lung diseases, such as asthma and COPD, as has already been shown for variants and differential gene expression in TGF?1.

Public Health Relevance

The overall short-term goals of this project are to 1) use whole-genome arrays to identify gene expression profiles in respiratory epithelium and transformed lymphocytes that associate with severity of CF lung disease, and 2) use expression quantitative-trait mapping (eQTL;genetical genomics) to define the relation between DNA, RNA, and CF lung phenotype. The long-term goal of this project is to develop better understanding of the molecular phenotype of CF lung disease, which will lead to the ability to predict non-CFTR related genetic risk, and develop new therapies.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL095396-04
Application #
8109359
Study Section
Special Emphasis Panel (ZHL1-CSR-K (S1))
Program Officer
Gan, Weiniu
Project Start
2008-09-24
Project End
2012-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
4
Fiscal Year
2011
Total Cost
$714,831
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Polineni, Deepika; Dang, Hong; Gallins, Paul J et al. (2018) Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity. Am J Respir Crit Care Med 197:79-93
Auer, Paul L; Nalls, Mike; Meschia, James F et al. (2015) Rare and Coding Region Genetic Variants Associated With Risk of Ischemic Stroke: The NHLBI Exome Sequence Project. JAMA Neurol 72:781-8
Corvol, Harriet; Blackman, Scott M; Boƫlle, Pierre-Yves et al. (2015) Genome-wide association meta-analysis identifies five modifier loci of lung disease severity in cystic fibrosis. Nat Commun 6:8382
O'Neal, Wanda K; Gallins, Paul; Pace, Rhonda G et al. (2015) Gene expression in transformed lymphocytes reveals variation in endomembrane and HLA pathways modifying cystic fibrosis pulmonary phenotypes. Am J Hum Genet 96:318-28
Guo, Xueliang; Zheng, Shuo; Dang, Hong et al. (2014) Genome reference and sequence variation in the large repetitive central exon of human MUC5AC. Am J Respir Cell Mol Biol 50:223-32
Norton, Nadine; Li, Duanxiang; Rampersaud, Evadnie et al. (2013) Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. Circ Cardiovasc Genet 6:144-53
Blackman, Scott M; Commander, Clayton W; Watson, Christopher et al. (2013) Genetic modifiers of cystic fibrosis-related diabetes. Diabetes 62:3627-35
Sun, Lei; Rommens, Johanna M; Corvol, Harriet et al. (2012) Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat Genet 44:562-9
Wright, Fred A; Strug, Lisa J; Doshi, Vishal K et al. (2011) Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2. Nat Genet 43:539-46
Sun, Wei; Wright, Fred A; Tang, Zhengzheng et al. (2009) Integrated study of copy number states and genotype calls using high-density SNP arrays. Nucleic Acids Res 37:5365-77